DNA Gene Gone Rogue Could Help 30% of Cancer Patients

A DNA repair gene that's supposed to protect your cells just revealed an unexpected superpower for fighting cancer.

Researchers at Penn State College of Medicine found that when cells produce too much of a gene called EXO1, it switches from helpful repairman to reckless saboteur. Instead of fixing DNA damage, excess EXO1 starts cutting apart healthy DNA structures, destabilizing cells in ways that can lead to cancer.

Here's where it gets interesting. The team discovered that EXO1 is overproduced in 20% to 30% of breast and ovarian cancers, plus melanoma, testicular, cervical, and liver cancers.

When EXO1 goes into overdrive, these tumors start behaving exactly like cancers caused by BRCA mutations—the inherited genetic changes that dramatically increase breast and ovarian cancer risk. But in this case, no BRCA mutation is present at all.

Think of EXO1 as molecular scissors. In normal amounts, it carefully trims damaged DNA during repairs. But when cells make too much, those scissors start snipping everything in sight, creating dangerous breaks in the genetic code.

Lead researcher Alexandra Nusawardhana found that excess EXO1 damages DNA through two main pathways, both creating toxic lesions that make cancer cells more fragile. "We ultimately think this is what makes the tumor more sensitive to chemotherapy and increases cell death," she explained.

The team tested whether these EXO1-overexpressing tumors would respond to olaparib, a drug designed for BRCA-mutant cancers that's known for having fewer side effects than traditional chemotherapy. The tumors were highly sensitive to the treatment.

The Bright Side

This discovery could expand access to gentler, more targeted cancer treatments for thousands of patients who wouldn't otherwise qualify for them.

"The same drugs that are reserved for treating BRCA-mutant tumors could potentially be used to treat EXO1-overexpressing tumors," said senior researcher George-Lucian Moldovan, professor of molecular and precision medicine. "It would expand the applicability of those drugs."

Right now, only patients with confirmed BRCA mutations can access certain targeted therapies. Testing for EXO1 levels could identify many more patients whose cancers share the same vulnerabilities, opening the door to more personalized treatment plans with better outcomes.

The research team analyzed tumor data from The Cancer Genome Atlas and found elevated EXO1 especially common in basal-like breast cancer, an aggressive form of the disease that's historically difficult to treat.

Unlike BRCA mutations, EXO1 overexpression isn't inherited and researchers don't yet know if it directly causes cancer. But as a biomarker, it could help doctors predict which patients will respond best to specific treatments.

Sometimes a gene's weakness becomes medicine's strength.